Mansi Shah

Employment

• Rutgers Cancer Institute of New Jersey

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (9)

• Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma
  Blood Cancer Journal 2026 DOI: 10.1038/s41408-026-01613-9
  +Save
• Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1
  Blood Neoplasia 2026 DOI: 10.1016/j.bneo.2026.100225
  +Save
• The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma
  2026 DOI: 10.21203/rs.3.rs-9451393/v1
  +Save
• Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses
  Clinical Lymphoma Myeloma and Leukemia 2026 DOI: 10.1016/j.clml.2025.11.004
  +Save
• The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia
  Blood Advances 2025 DOI: 10.1182/bloodadvances.2025016695
  +Save
• Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
  Journal of Clinical Oncology 2024 DOI: 10.1200/JCO.24.01008
  +Save
• COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination
  Clinical Lymphoma Myeloma and Leukemia 2022 DOI: 10.1016/j.clml.2021.11.001
  +Save
• Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer
  Cancer Discovery 2022 DOI: 10.1158/2159-8290.CD-21-1368
  +Save
• SARS‐CoV‐2 nosocomial infection: Real‐world results of environmental surface testing from a large tertiary cancer center
  Cancer 2021 DOI: 10.1002/cncr.33453
  +Save